新型广谱唑类抗真菌药艾沙康唑的研究进展

摘要/Abstract

中图分类号:

R 978.5

赵旭初, 胡爱玲. 新型广谱唑类抗真菌药艾沙康唑的研究进展[J]. 中国真菌学杂志, 2023, 18(3): 265-269.

[1] BROWN G D, DENNING D W, GOW N A,et al. Hidden killers: Human fungal infections[J]. Sci Transl Med,2012, 4(165):165rv13.
[2] BONGOMIN F, GAGO S, OLADELE R O, et al. Global and multi-national prevalence of fungal diseases-estimate precision[J].J Fungi (Basel), 2017, 3(4):57.
[3] GALLAGHER J C, DODDS ASHLEY E S, DREW R H,et al.Antifungal pharmacotherapy for invasive mould infections[J]. Expert Opin Pharmacother, 2003, 4(2): 147-164.
[4] LIVERMORE J, HOPE W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections[J]. Expert Opin Drug Metab Toxicol, 2012, 8(6):759-765.
[5] JENKS J D, SALZER H J, PRATTES J, et al. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy[J]. Drug Des Dev Ther,2018,12:1033-1044. DOI:10.2147/DDDT.S145545.
[6] SCHMITT-HOFFMANN A, DESAI A, KOWALSKI D, et al. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH[J]. Int. J Clin Pharmacol Ther,2016,54(8):572-580.
[7] KOVANDA L L, MARTY F M, MAERTENS J, et al. Impact of mucositis on absorption and systemic drug exposure of isavuconazole[J]. Antimicrob Agents Chemother,2017,61(6):e00101-17.
[8] SCHMITT-HOFFMANN A, ROOS B, HEEP M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers[J]. Antimicrob Agents Chemother,2006,50(1):279-285.
[9] SCHMITT-HOFFMANN A, ROOS B, MAARES J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers[J]. Antimicrob Agents Chemother,2006,50(1):286-293.
[10] EVERSON N,SMITH J, GARNER D. Successful treatment of contaminated epidural steroid associated fungal menigitis with isauvconazole. In proceedings of the European Congress of Clinical Microbiology And Infectious Disease (ECCMID)[J].Ann Clin Microbiol Antimicrob,2022,21(1):42.
[11] SCHMITT-HOFFMANN A H, KATO K, TOWNSEND R,et al.Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats[J]. Antimicrob Agents Chemother,2017,61(12):e01292-17.
[12] KOVANDA L L, DESAI A V, LU Q, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)[J]. Antimicrob Agents Chemother,2016,60(8):4568-4576.
[13] KAINDL T,ANDES D, ENGELHARDT M,et al.Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases[J]. Antimicrob Chemother,2019,74(3):761-767.
[14] TOWNSEND R W,AKHTAR S,ALCORN H,et al.Phase Ⅰ trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics[J]. Eur J Clin Pharmacol,2017,73(6):669-678.
[15] ZURL C,WALLER M,SCHWAMEIS F,et al.Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: Outcome, tolerability and clinical implications of isavuconazole plasma concentrations[J]. J Fungi,2020,6(2):90.
[16] ZHAO Y,SEELHAMMER T G, BARRETO E F,et al. Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation[J]. Pharmacotherapy,2020,40(1):89-95.
[17] ANDES D,KOVANDA L,DESAI A,et al.Isavuconazole concentration in real-world practice: Consistency with results from clinical trials[J]. Antimicrob Agents Chemother,2018,62(7):e00585-18.
[18] PATTERSON T F, THOMPSON G R,DENNING D W,et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis,2016,63(4):433-442.
[19] TISSOT F, AGRAWAL S, PAGANO L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J]. Haematologica,2017,102(3):433-444.
[20] GUINEA J, PELÁEZ T, RECIO S,et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species[J]. Antimicrob Agents Chemother,2008,52(4):1396-1400.
[21] ASTVAD K M T, HARE R K,ARENDRUP M C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates[J]. Clin Microbiol Infect,2017,23(11):882-887.
[22] SEIFERT H, AURBACH U,STEFANIK D,et al. In vitro activities of isavuconazole and other antifungal agents against candida bloodstream isolates. antimicrob[J]. Agents Chemother,2007,51(5):1818-1821.
[23] ESPINEL-INGROFF A,CHOWDHARY A,GONZALEZ G M,et al.Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method[J]. Antimicrob Agents Chemother,2015,59(1):666-668.
[24] OSEI SEKYERE J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen[J]. Microbiologyopen,2018, 7(4):e00578.
[25] DATTA K, RHEE P, BYRNES E,et al.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility[J]. J Clin Microbiol,2013,51(9):3090-3093.
[26] ARENDRUP M C,JENSEN R H, Meletiadis, J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order[J]. Antimicrob Agents Chemother,2015,59(12):7735-7742.
[27] Astellas Pharma US & Inc. CRESEMBA (isavuconazonium_sulfate) Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf.
[28] KIEU V,JHANGIANI K, DADWAL S,et al.Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study[J]. Transpl Infect Dis,2019,21(1):e13007.
[29] KONTOYIANNIS D P,MARR K A,PARK B J,et al.Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) database[J]. Clin Infect Dis,2010, 50(8):1091-1100.
[30] MAERTENS J A, RAAD I I, MARR K A,et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial[J]. Lancet,2016,387(10020):760-769.
[31] BONGOMIN F, MAGUIRE N, MOORE C B,et al.Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events[J]. Mycoses,2019,62(3):217-222.
[32] HARRINGTON R,LEE E, YANG H,et al.Cost-effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive aspergillosis[J]. Adv Ther,2017,34(1):207-220.
[33] FLOROS L, PAGLIUCA A, TAIE A A,et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom[J]. J Med Econ,2020,23(1):86-97.
[34] FLOROS L, KUESSNER D, POSTHUMUS J,et al.Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden[J]. BMC Infect Dis,2019,19(1):134.
[35] ULLMANN A J, AGUADO J M, ARIKAN-AKDAGLI S,et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect,2018,24 (Suppl 1):e1-e38.
[36] PETRIKKOS G, SKIADA A,LORTHOLARY O,et al. Epidemiology and clinical manifestations of mucormycosis[J]. Clin Infect Dis,2012,54 (Suppl 1):S23-S34.
[37] PERFECT J R, CORNELY O A, HEEP M,et al.Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial[J]. Mycoses,2018,61(7):420-429.
[38] MARTY F M, OSTROSKY-ZEICHNER L, CORNELY O A,et al.VITAL and fungiscope mucormycosis investigators. isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis,2016,16(7):828-837.
[39] ASHKENAZI-HOFFNUNG L,BILAVSKY E,LEVY I,et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients[J]. Pediatr Infect Dis,2020,39(8):718-724.
[40] ILHARCO M, PEREIRA C M, MOREIRA L,et al. Rhinoorbital mucormycosis in the immunocompetent: experience with isavuconazole[J]. IDCases, 2019,18:e00591. DOI: 10.1016/j.idcr.2019.e00591.
[41] SHAFIQ M, ALI Z, UKANI R,et al.Isavuconazole: A promising salvage therapy for invasive mucormycosis[J]. Cureus,2018,10(4):e2547.
[42] RICOTTA E E, LAI Y L, BABIKER A,et al. Invasive candidiasis species distribution and trends, United States[J]. Infect Dis, 2021,223(7):1295-1302.
[43] PFALLER M A, DIEKEMA D J. Epidemiology of invasive candidiasis: A persistent public health problem[J]. Clin Microbiol Rev,2007,20(1):133-163.
[44] KULLBERG B J, VISCOLI C, PAPPAS P G,et al.Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE trial[J]. Clin Infect Dis,2019,68(12):1981-1989.
[45] KEIRNS J, DESAI A, KOWALSKI D,et al. QT interval shortening with isavuconazole: In vitro and in vivo effects on cardiac repolarization[J]. Clin Pharmacol Ther,2017,101(6):782-790.
[46] MELLINGHOFF S C, BASSETTI M, DÖRFEL D,et al.Isavuconazole shortens the QT interval[J]. Mycoses,2018,61(4):256-260.
[47] WILSON D T, DIMONDI V P, JOHNSON S W,et al.Role of isavuconazole in the treatment of invasive fungal infections[J]. Ther Clin Risk Manag,2016,12:1197-1206.DOI: 10.2147/TCRM.S90335. eCollection 2016.
[48] SANGLARD D,COSTE A T. Activity of isavuconazole and other azoles against candida clinical isolates and yeast model systems with known azole resistance mechanisms[J]. Antimicrob Agents Chemother,2015,60(1):229-238.
[49] JØRGENSEN K M, ASTVAD K M T,HARE R K,et al. EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates[J]. Antimicrob Agents Chemother,2019,63(6):e00073-19.

新型广谱唑类抗真菌药艾沙康唑的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	宋晓婷, 赵作涛, 王爱平. 新型系统性抗真菌药物研究进展[J]. 中国真菌学杂志, 2023, 18(4): 370-376.
[2]	邓劲, 殷琳, 江海燕, 旷凌寒, 彭溪, 杨向贵, 倪苏娇, 张帮勤, 冯金芳, 王燕玲, 马瑜珊, 陈宗耀, 钟涵宇, 吴贤丽, 黎昆, 王玲, 高伟, 杨学强, 朱军, 陈喻, 张弦, 孙昌君, 罗军, 李玉梅, 李彦, 张兵, 谢宁, 王俊, 谢轶, 康梅. 2019—2021年四川省血流感染病原真菌分布特征及药敏分析[J]. 中国真菌学杂志, 2023, 18(3): 198-204,210.
[3]	方婷婷, 何伊能, 王慧, 傅宏阳, 李园园, 曹毅, 陶茂灿. 浅部真菌病治疗中存在的问题及中医治疗对策[J]. 中国真菌学杂志, 2023, 18(1): 38-41.
[4]	吴雨娴, 张旺喆麒, 徐洋, 柴晓云. 基于抗真菌药物的近红外荧光探针研究进展[J]. 中国真菌学杂志, 2022, 17(5): 431-434.
[5]	杨之辉, 李若瑜. 浅部真菌感染中的抗真菌药物治疗进展[J]. 中国真菌学杂志, 2022, 17(4): 339-348.
[6]	高路, 吕权真, 甄诚, 阎澜, 姜远英. 化学基因组学在抗真菌药物研究中的应用[J]. 中国真菌学杂志, 2022, 17(3): 235-240.
[7]	肖湘. 泌尿系念珠菌感染的抗真菌药物合理选用[J]. 中国真菌学杂志, 2022, 17(3): 241-243,264.
[8]	唐人杰, 王瑞娜, 王智, 刘海燕, 刘旭, 李红磊, 刘佳存, 张大志, 阎澜. 某院校学员浅部真菌病调查分析[J]. 中国真菌学杂志, 2022, 17(2): 120-123.
[9]	王会伟, 姜伟伟, 徐媛, 李颖芳, 李航, 朱信霖, 陈天杨, 王启龙, 陈敏, 潘炜华, 廖万清. 中国大陆地区Fonsecaea临床分离株的体外抗真菌药物敏感性特征[J]. 中国真菌学杂志, 2022, 17(2): 132-136.
[10]	郁谨菡, 赵颖, 徐英春. 机会性致病真菌解脂耶氏酵母研究进展[J]. 中国真菌学杂志, 2022, 17(2): 168-172.
[11]	陈雪雯, 陈裕充, 温海. 部分新型外用唑类抗真菌药物治疗浅部真菌病的研究进展[J]. 中国真菌学杂志, 2022, 17(1): 55-58.
[12]	康烨, 王瑞娜, 阎澜. 抗真菌药物潜在靶点及化合物研究进展[J]. 中国真菌学杂志, 2021, 16(6): 414-419.
[13]	徐灵玲, 曾章锐, 丁银环, 杨葵. 川南地区侵袭性念珠菌感染流行病学及耐药性分析[J]. 中国真菌学杂志, 2021, 16(5): 319-325.
[14]	谭静文, 高志琴, 杨虹, 杨连娟. 国产泊沙康唑对生殖器来源念珠菌的体外药物敏感性研究[J]. 中国真菌学杂志, 2021, 16(5): 326-329,334.
[15]	张欠欠, 罗传玉, 陈嘉琪, 封小川. 白念珠菌感染现状及抗真菌药物研究进展[J]. 中国真菌学杂志, 2021, 16(5): 356-360.